selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis
This new clinical study is designed as a multicenter, Phase 1b, double-blind, placebo-controlled trial in adults with mild to severe Ps or PsA.
- This new clinical study is designed as a multicenter, Phase 1b, double-blind, placebo-controlled trial in adults with mild to severe Ps or PsA.
- The Company anticipates enrolling up to 40 patients with Ps, of which up to 16 patients may also have PsA.
- This psoriasis study follows the recent completion of the Company’s first-in-human Phase 1b trial in atopic dermatitis patients, in which the Company observed safety and tolerability of si-544 in adult patients with mild to severe atopic dermatitis.
- The current Phase 1b trial design in patients with Ps or PsA should also allow for the evaluation of efficacy signals.